G.A. Ellard

2.9k total citations
68 papers, 2.1k citations indexed

About

G.A. Ellard is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, G.A. Ellard has authored 68 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Infectious Diseases, 18 papers in Epidemiology and 13 papers in Molecular Biology. Recurrent topics in G.A. Ellard's work include Tuberculosis Research and Epidemiology (18 papers), Leprosy Research and Treatment (14 papers) and Mycobacterium research and diagnosis (7 papers). G.A. Ellard is often cited by papers focused on Tuberculosis Research and Epidemiology (18 papers), Leprosy Research and Treatment (14 papers) and Mycobacterium research and diagnosis (7 papers). G.A. Ellard collaborates with scholars based in United Kingdom, Tanzania and United States. G.A. Ellard's co-authors include Patricia T. Gammon, D A Mitchison, Wallace Fox, Peter Jenner, D.A. Mitchison, Michael Humphries, Jean M. Dickinson, R. J. W. Rees, Richard Morris and H Peach and has published in prestigious journals such as Nature, The Lancet and British Journal of Pharmacology.

In The Last Decade

G.A. Ellard

64 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G.A. Ellard United Kingdom 25 1.1k 710 463 351 350 68 2.1k
Ihor Bekersky United States 32 1.5k 1.4× 1.1k 1.5× 494 1.1× 375 1.1× 310 0.9× 69 3.7k
John G. Gambertoglio United States 31 565 0.5× 648 0.9× 138 0.3× 210 0.6× 320 0.9× 91 2.4k
James J. Keirns United States 34 1.5k 1.4× 875 1.2× 180 0.4× 260 0.7× 1.1k 3.1× 88 3.9k
Raymond S. Koff United States 37 604 0.6× 2.4k 3.3× 559 1.2× 455 1.3× 471 1.3× 151 4.8k
Howard Greenberg United States 26 476 0.4× 294 0.4× 355 0.8× 332 0.9× 209 0.6× 63 2.1k
B G Gazzard United Kingdom 25 933 0.9× 703 1.0× 354 0.8× 386 1.1× 128 0.4× 59 2.4k
Ralph E. Cutler United States 32 266 0.3× 367 0.5× 367 0.8× 210 0.6× 485 1.4× 80 3.0k
Keith Gallicano Canada 26 1.3k 1.2× 488 0.7× 159 0.3× 533 1.5× 297 0.8× 63 2.8k
Robert L. Talbert United States 31 230 0.2× 494 0.7× 407 0.9× 194 0.6× 326 0.9× 117 2.7k
Jussi Saukkonen United States 23 1.2k 1.1× 1.0k 1.4× 575 1.2× 645 1.8× 572 1.6× 51 3.0k

Countries citing papers authored by G.A. Ellard

Since Specialization
Citations

This map shows the geographic impact of G.A. Ellard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G.A. Ellard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G.A. Ellard more than expected).

Fields of papers citing papers by G.A. Ellard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G.A. Ellard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G.A. Ellard. The network helps show where G.A. Ellard may publish in the future.

Co-authorship network of co-authors of G.A. Ellard

This figure shows the co-authorship network connecting the top 25 collaborators of G.A. Ellard. A scholar is included among the top collaborators of G.A. Ellard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G.A. Ellard. G.A. Ellard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ellard, G.A., Patricia T. Gammon, John A. Savin, & R. Tan. (2006). Dapsone acetylation in dermatitis herpetiformis. British Journal of Dermatology. 90(4). 441–444. 1 indexed citations
2.
Pillai, Gopal S, et al.. (2001). The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.. PubMed. 5(8). 691–5. 9 indexed citations
3.
Fox, Wallace, G.A. Ellard, & D A Mitchison. (1999). Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.. PubMed. 3(10 Suppl 2). S231–79. 450 indexed citations
4.
McIlleron, Helen, et al.. (1999). The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.. PubMed. 3(11 Suppl 3). S329–35; discussion S351. 2 indexed citations
5.
Chan, Stephen L., Wing Wai Yew, B.W. Allen, et al.. (1994). Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. International Journal of Antimicrobial Agents. 3(4). 267–274. 16 indexed citations
6.
Ellard, G.A., et al.. (1993). Cerebrospinal Fluid Drug Concentrations and the Treatment of Tuberculous Meningitis. American Review of Respiratory Disease. 148(3). 650–655. 100 indexed citations
7.
Ellard, G.A.. (1991). The use of RNA/DNA ratio measurements to assess rifampicin-induced growth inhibition of Escherichia coli. Journal of Antimicrobial Chemotherapy. 28(3). 347–355. 5 indexed citations
8.
Jenner, Peter & G.A. Ellard. (1989). Isoniazid-related hepatotoxicity: A study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. Tubercle. 70(2). 93–101. 11 indexed citations
9.
Colston, M. Joseph, G.A. Ellard, J Grosset, et al.. (1988). Characteristics of the multiplication of dapsone-resistant strains of Mycobacterium leprae in mice. Leprosy Review. 59(1). 5–10.
10.
Peach, H, et al.. (1985). A simple, inexpensive urine test of smoking.. Thorax. 40(5). 351–357. 75 indexed citations
11.
Gurumurthy, Prema, R Parthasarathy, G.R.K. Sarma, et al.. (1984). Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.. PubMed. 129(1). 58–61. 54 indexed citations
12.
Pearson, J. M. H., et al.. (1983). An investigation of dapsone compliance using an isoniazid-marked formulation. Leprosy Review. 54(4). 317–25. 7 indexed citations
13.
Mitchison, D A & G.A. Ellard. (1980). Tuberculosis in patients having dialysis.. BMJ. 280(6224). 1186.2–1186. 5 indexed citations
14.
Colston, M. Joseph, G. R. F. Hilson, G.A. Ellard, Patricia T. Gammon, & R. J. W. Rees. (1978). The Activity of Thiacetazone, Thiambutosine, Thiocarlide and Sulphamethoxypyridazine AgainstMycobacterium lepraein Mice. Leprosy Review. 49(2). 101–13. 8 indexed citations
15.
Dickinson, Jean M., V R Aber, B.W. Allen, G.A. Ellard, & D.A. Mitchison. (1974). Assay of rifampicin in serum. Journal of Clinical Pathology. 27(6). 457–462. 29 indexed citations
16.
Ellard, G.A., Jean M. Dickinson, Patricia T. Gammon, & D.A. Mitchison. (1974). Serum concentrations and antituberculosis activity of thiacetazone. Tubercle. 55(1). 41–54. 13 indexed citations
17.
Ellard, G.A., et al.. (1972). Dapsone Acetylation and the Treatment of Leprosy. Nature. 239(5368). 159–160. 28 indexed citations
18.
Dickinson, Jean M., G.A. Ellard, & D.A. Mitchison. (1968). Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle. 49(4). 351–366. 58 indexed citations
19.
Ellard, G.A.. (1966). ABSORPTION, METABOLISM AND EXCRETION OF DI(p‐AMINOPHENYL) SULPHONE (DAPSONE) AND DI(p‐AMINOPHENYL) SULPHOXIDE IN MAN. British Journal of Pharmacology and Chemotherapy. 26(1). 212–217. 25 indexed citations
20.
Ellard, G.A.. (1966). A Preliminary Study of the Absorption, Metabolism and Excretion of Injectable Thiambutosine. Leprosy Review. 37(1). 17–22. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ihor Bekersky Breakdown of academic impact, for papers by John G. Gambertoglio Breakdown of academic impact, for papers by James J. Keirns Breakdown of academic impact, for papers by Raymond S. Koff Breakdown of academic impact, for papers by Howard Greenberg Breakdown of academic impact, for papers by B G Gazzard Breakdown of academic impact, for papers by Ralph E. Cutler Breakdown of academic impact, for papers by Keith Gallicano Breakdown of academic impact, for papers by Robert L. Talbert Breakdown of academic impact, for papers by Jussi Saukkonen
Rankless by CCL
2026